Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;50(1):110-113.
doi: 10.1111/imj.14652.

Ischaemic stroke and transient ischaemic attack on anticoagulants: outcomes in the era of direct oral anticoagulants

Michael Valente  1 , Shelton Leung  1 , Philip Wu  1 , Danielle H Oh  2   3 , Hyuen Tran  3   4 , Philip M C Choi  1   3
Affiliations

Ischaemic stroke and transient ischaemic attack on anticoagulants: outcomes in the era of direct oral anticoagulants

Michael Valente et al. Intern Med J. 2020 Jan.

Abstract

Clinical and imaging characteristics of patients receiving direct oral anticoagulants presenting with transient ischaemic attack or stroke are lacking. A retrospective review of all patients who presented to a high-volume primary stroke centre with acute stroke symptoms while prescribed an oral anticoagulant between January 2012 and June 2017. Clinical, radiological characteristics and functional outcomes were examined. Anticoagulated patients diagnosed with stroke or transient ischaemic attack shared similar disease and outcome characteristics irrespective of anticoagulants used. One-third of warfarin patients with sub-therapeutic international normalised ratios were treated with thrombolytics but no direct oral anticoagulants level was performed in any of the patients, with only one treated by intravenous thrombolysis.

Keywords: anticoagulant; direct oral anticoagulant; stroke; transient ischaemic attack; warfarin.

PubMed Disclaimer

References

    1. Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian atrial fibrillation study: transition to direct oral anticoagulants 2011-2015. Cardiovasc Ther 2017; 35: 1-9.
    1. Morgan A, Joshy G, Schaffer A, Laba TL, Litchfield M, Pearson S et al. Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. PLoS One 2018; 13: e0208824.
    1. Pol D, Curtis C, Ramkumar S, Bittinger L. NOACs now mainstream for the use of anticoagulation in non-valvular atrial fibrillation in Australia. Heart Lung Circ 2019; 28: e40-e2.
    1. Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol 2019; 34: 173-90.
    1. Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - a national case collection. Int J Stroke 2017; 12: 383-91.

LinkOut - more resources